An implantable brain-computer interface using Axoft's proprietary Fleuron material to record signals from neurons. The soft polymer reduces scarring and improves long-term signal stability compared to existing implants.
PilotStage 3 of 5
First-in-human trials ongoing with 11+ patients; preparing for U.S. regulatory approval.
Updated Apr 2026·Checked 10 Oct·0 updates this week
Milestones
Next · GMP manufacturing facility construction
Seed funding2022Complete.
FDA Breakthrough Device Designation grantedOct 2022Complete.
First-in-human trials begin at Panama ClinicMar 2025Complete.
Nature publication of trial resultsDec 2023Complete.
Panama Clinic study completed with 4 patientsApr 2025Complete.
2026GMP manufacturing facility construction (next)
2027GMP manufacturing facility opens
2027FDA Breakthrough Device Designation request
Current obstacles
Manufacturing complexityFleuron implants are difficult to scale. Each thread must be thin, flexible, and precisely positioned. Axoft is building a GMP facility.
Regulatory pathwaySoft implants are relatively new. The FDA has not yet approved this class of device, so Axoft must define the regulatory path and prove safety and efficacy.
Physics limits
Electrode lifetimeElectrodes degrade over time as the metal surface reacts with brain chemistry. Even softer implants face this limit; advances come from better electrode materials, not material science alone.
Insertion traumaA needle can only be so thin before it bends. Thinner needles mean less trauma but also more difficulty steering to the right location in the brain.
How it works
3 parts
Implantation
Soft thread array
Fleuron threads are flexible enough to be threaded through a hollow needle into the brain, then detach, reducing trauma compared to stiff electrodes.
Recording
High-density electrodes
Each thread carries many electrodes to detect individual neuron spikes. The softness allows denser arrays in the same brain region.
Integration
Minimal scar tissue
Soft polymer mimics brain tissue, so the immune system treats it as native. Less scarring means stable recordings years post-implant.
Axoft develops implantable brain-computer interfaces using Fleuron, 10,000x softer than polyimide. The material reduces scarring and improves recording stability. Founded 2021 in Cambridge, completed first-in-human trials with 11+ patients and raised $55M Series A in April 2026.
Fleuron enables 8x more region access and 32x more sensors per thread than standard flexible probes.
Clinical collaboration with Mass General Brigham and The Panama Clinic, with research published in Nature.
Subsidiary in Grenoble, France opened to support European expansion and manufacturing.
